umbralisib

Effect of Sophocarpine on the Pharmacokinetics of Umbralisib in Rat Plasma Using a Novel UPLC-MS/MS Method

Frontiers - 20 Jan 2022
Effect of Sophocarpine on the Pharmacokinetics of Umbralisib in Rat Plasma Using a Novel UPLC-MS/MS Method ...

Could hidden signals in public data have anticipated bad news for TG Therapeutics $TGTX?

STAT - 13 Sep 2022
Could hidden signals in public data have anticipated bad news for TG Therapeutics $TGTX? ...

Umbralisib: Walking the Tightrope of PI3K Inhibition in Indolent NHL

ASCO Journals - 16 Apr 2021
Umbralisib: Walking the Tightrope of PI3K Inhibition in Indolent NHL ...

Lindsey Roeker, MD, Discusses the Outcomes of Using Ibrutinib With Umbralisib/Ublituximab in CLL

Cancer Network - 09 Jan 2022
Lindsey Roeker, MD, Discusses the Outcomes of Using Ibrutinib With Umbralisib/Ublituximab in CLL ...

Umbralisib plus ublituximab benefits patients with CLL and Bruton TKI risk factors

Healio - 14 Dec 2021
Umbralisib plus ublituximab benefits patients with CLL and Bruton TKI risk factors ...

Watch out, Gilead: TG Therapeutics wins FDA nod for potentially safer Zydelig rival

FiercePharma - 08 Feb 2021
Watch out, Gilead: TG Therapeutics wins FDA nod for potentially safer Zydelig rival ...

Recent advances in treatment of follicular lymphoma: efficacy of PI3Kα/δ inhibitor (TQ-B3525)

Nature.com - 16 May 2024
Recent advances in treatment of follicular lymphoma: efficacy of PI3Kα/δ inhibitor (TQ-B3525) ...

FDA Grants Orphan Drug Status to Umbralisib for Follicular Lymphoma

Lymphoma News Today - 19 Mar 2020
FDA Grants Orphan Drug Status to Umbralisib for Follicular Lymphoma ...

FDA Withdraws Approval of Ukoniq Over Safety Concerns - MPR

Monthly Prescribing Reference - 02 Jun 2022
FDA Withdraws Approval of Ukoniq Over Safety Concerns - MPR ...

Lessons learned from postmarketing withdrawals of expedited approvals for oncology drug indications

The Lancet - 28 May 2024
Lessons learned from postmarketing withdrawals of expedited approvals for oncology drug indications ...

Lymphoma Drug Copanlisib to Be Pulled From U.S. Market

Medpage Today - 14 Nov 2023
Lymphoma Drug Copanlisib to Be Pulled From U.S. Market ...

Targeting Two Types of Lymphoma

American Association for Cancer Research (AACR) - 17 Feb 2021
Targeting Two Types of Lymphoma ...

Rhizen Pharmaceuticals gets USFDA nod for cancer drug Umbralisib

BusinessLine - 09 Feb 2021
Rhizen Pharmaceuticals gets USFDA nod for cancer drug Umbralisib ...

Phase III UNITY-CLL Trial Shows Promise for Umbralisib, Ublituximab Combo in CLL

Cancer Network - 06 May 2020
Phase III UNITY-CLL Trial Shows Promise for Umbralisib, Ublituximab Combo in CLL ...

TG Therapeutics rethinks oncology as stock stumbles

BioWorld Online - 18 Apr 2022
TG Therapeutics rethinks oncology as stock stumbles ...

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

Journal of Clinical Pathways - 09 Jun 2022
Overview of the Updated NCCN Guidelines on B-Cell Lymphomas ...

For Certain NHLs, TG Seeks Accelerated FDA Approval of Umbralisib

Lymphoma News Today - 28 Jan 2020
For Certain NHLs, TG Seeks Accelerated FDA Approval of Umbralisib ...

Ukoniq Approved for Marginal Zone Lymphoma, Follicular Lymphoma

Monthly Prescribing Reference - 09 Feb 2021
Ukoniq Approved for Marginal Zone Lymphoma, Follicular Lymphoma ...

Determining drug dose in the era of targeted therapies: playing it (un)safe?

Nature.com - 23 Aug 2022
Determining drug dose in the era of targeted therapies: playing it (un)safe? ...